Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | COVID-19 & multiple myeloma: patient management

Florent Malard • 20 Aug 2020
EBMT 2020
Multiple Myeloma

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the management of patients with multiple myeloma during the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

Results of a survey investigating fertility and outcomes after CAR T-cell therapy
1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes
1:17
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes
Florent Malard • 31 Mar 2025
The potential of microbiome modulation for preventing and treating acute GvHD
1:04
The potential of microbiome modulation for preventing and treating acute GvHD
Florent Malard • 31 Mar 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Florent Malard • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Florent Malard • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Florent Malard • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Florent Malard • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals